Skip to main content
Article thumbnail
Location of Repository

The Use of Clinical Utility Assessments in Early Clinical Development

By Anis A. Khan, Itay Perlstein and Rajesh Krishna

Abstract

A quickly realizable benefit of model-based drug development is in reducing uncertainty in risk/benefit, comprising individually of safety and effectiveness, two key attributes of a product evaluated for regulatory approval, marketing, and use. In this review, we investigate gaps and opportunities in using fundamental decision analytic principles in drug development and present a quantitative clinical pharmacology framework for the application of such aids for early clinical development decision making. We anticipate that implementation of such emerging tools will enable sufficient scientific understanding of the two attributes to facilitate the early termination of compounds with less than desirable risk/benefit profiles and continuance of compounds with acceptable risk/benefit profiles

Topics: Quantitative Pharmacology, a Roadmap for Rational, Model-Based Drug Development
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:2664875
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.